Suven Receives Product Patents in Europe, South Korea | CORPORATE ETHOS

Suven Receives Product Patents in Europe, South Korea

By: | July 16, 2018
suven life sciences
Jul 16: Hyderabad-based biopharmaceutical firm Suven Life Sciences Ltd on Monday announced that the company has been granted one product patent from Europe (2976337) and another one product patent from South Korea (10-1860487) corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2033 and 2034.
According to the company, the granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.